Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs

Exclusion Criteria

• •Patients will not be eligible for this study if they:
• •Have used a protease inhibitor for more than 14 days.
• •Have used ddI or d4T for more than 30 days.
• •Are pregnant or breast-feeding.
• •Have an opportunistic (AIDS-related) infection requiring treatment at the time of enrollment.
• •Have, or appear to have, peripheral neuropathy (a painful condition affecting the nervous system) at the time of screening.
• •Are at risk for, or have had, pancreatitis (disease of the pancreas).
• •Have difficulty absorbing medications.
• •Have a cancer, other than Kaposi's sarcoma, that may require systemic treatment.
• •Have any medical condition or treatment that may cause a rise in viral load.
• •Have any other condition or previous treatment that would interfere with the study.
• •Are unable to take drugs by mouth.
• •Are receiving or have received recently any of the following drugs: terfenadine, astemizole, cisapride, triazolam, midazolam, ergot alkaloids, amiodarone, bepridil, flecainide, propafenone, quinidine, pimozide, rifampin, and intravenous (IV) pentamidine.
• •Are receiving vincristine, thalidomide, foscarnet, or cisplatin or other medications that may cause nerve damage.
• •Have received any experimental drug within 30 days prior to treatment.
• •Are receiving treatment with testosterone, anabolic steroids, growth hormone, or megestrol acetate, except for certain hormonal problems.